文献速递头颈外科

人工神经网络预测老年头颈癌放化疗结局

Outcome Prediction in Older Adults With Head and Neck Cancer Undergoing Chemoradiation.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2025-11-06

该国际队列研究基于SENIOR注册数据开发并外部验证人工神经网络,用于预测接受根治性放化疗的65岁以上局部晚期头颈部鳞癌患者的总生存期和无进展生存期。总生存期模型ROC-AUC为0.68(95%CI 0.60-0.76),无进展生存期模型ROC-AUC为0.64(95%CI 0.56-0.72),可将患者分层为高危和低危组。

要点

  • 人工神经网络模型可基于常规临床数据对老年头颈癌放化疗患者进行预后分层。
  • 总生存期模型ROC-AUC为0.68,无进展生存期模型为0.64。
  • HPV状态、肾功能、ECOG评分和淋巴结分期是重要预测特征。

核心结论

  • 基于人工神经网络的模型能有效将接受根治性放化疗的老年头颈部鳞癌患者分层为不同预后组。

研究设计与样本

  • 国际多中心回顾性队列研究,数据来自德国、瑞士、捷克、塞浦路斯和美国的19个学术癌症中心SENIOR注册库。
  • 纳入65岁及以上、局部晚期头颈部鳞癌、接受根治性放化疗的患者,排除诱导或辅助化疗、头颈癌病史及治疗开始时转移性疾病。
  • 总生存期分析纳入898例(训练队列738例,测试队列160例),无进展生存期分析纳入945例(训练队列770例,测试队列175例)。

主要发现

  • 总生存期人工神经网络将患者分为高危和低危组,生存差异显著,ROC-AUC为0.68(95%CI,0.60-0.76)。
  • 无进展生存期人工神经网络显示出相似区分度,ROC-AUC为0.64(95%CI,0.56-0.72)。
  • 最具预测性的特征包括HPV状态、肾功能(估算肾小球滤过率)、ECOG体能状态评分和淋巴结分期。

关键数值与推荐

  • 总生存期分析中位(IQR)年龄为71(68-76)岁,665例(74.1%)为男性。
  • 无进展生存期分析中位(IQR)年龄为71(68-76)岁,696例(73.7%)为男性。

临床怎么用

  • 人工神经网络模型可整合到临床工作流程中,辅助老年头颈癌患者的个体化治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Older adults with head and neck squamous cell carcinoma (HNSCC) are underrepresented in clinical trials, limiting evidence-based treatment decisions. Artificial neural networks (ANNs) have demonstrated the ability to personalize treatment recommendations using patient-specific characteristics. OBJECTIVE: To develop and externally validate ANNs for overall survival (OS) and progression-free survival (PFS) in older adults with HNSCC undergoing definitive chemoradiation. DESIGN, SETTING, AND PARTICIPANTS: This international cohort study included retrospective clinical data from 19 academic cancer centers across Germany, Switzerland, Czech Republic, Cyprus, and the US from the SENIOR registry. ANNs were developed and validated using data from patients 65 years and older with locoregionally advanced HNSCC treated with definitive chemoradiation. Exclusion criteria included induction or adjuvant chemotherapy, history of head and neck cancer, and metastatic disease at treatment initiation. Data were collected from January 2021 to December 2023, and data were analyzed from December 2023 to April 2025. EXPOSURES: All patients received definitive radiotherapy with concurrent systemic therapy between 2005 and 2019. MAIN OUTCOMES AND MEASURES: OS and PFS were predicted using 2 separate ANN models. Patients were classified as high or low risk based on median prediction thresholds. Model performance was assessed with receiver operating characteristic (ROC) area under the curve (AUC) and precision recall AUC. Model explainability was assessed with Shapley additive explanations values. RESULTS: Of 898 patients included in the OS analysis (738 in training cohort and 160 in testing cohort), 665 (74.1%) were male, and the median (IQR) age was 71 (68-76) years. Of 945 included in the PFS analysis (770 in training cohort and 175 in testing cohort), 696 (73.7%) were male, and the median (IQR) age was 71 (68-76) years. The OS ANN stratified patients into high-risk and low-risk groups with significantly different survival, achieving an ROC-AUC of 0.68 (95% CI, 0.60-0.76). The PFS ANN showed similar discrimination, with an ROC-AUC of 0.64 (95% CI, 0.56-0.72). Human papillomavirus status, kidney function (estimated glomerular filtration rate), Eastern Cooperative Oncology Group Performance Status score, and nodal classification were among the most predictive features. CONCLUSIONS AND RELEVANCE: In this study, ANN-based models using routine clinical data effectively stratified older adults with HNSCC into prognostic groups. Integration of ANNs into clinical workflows could support personalized treatment decisions for this vulnerable population.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Marschner SN, Lombardo E, Haehl E, et al. Outcome Prediction in Older Adults With Head and Neck Cancer Undergoing Chemoradiation. JAMA Otolaryngol Head Neck Surg. 2025. PMID: 41196615. doi:10.1001/jamaoto.2025.3840

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。